AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
3 clinical-grade skincare creams you really shouldn’t buy online 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
German healthcare and materials company Merck KGaA (NSE:PROR) announced on Monday that it has agreed to acquire U.S.-based biotech firm SpringWorks Therapeutics in a deal valued at approximately $3.9 billion. The acquisition is aimed at strengthening Merck’s oncology business and expanding its pipeline of cancer therapies.
The Darmstadt-headquartered group said it will pay $47 per share in cash for SpringWorks, representing a premium over the company’s recent trading price. The deal assigns SpringWorks an equity value of $3.9 billion and an enterprise value of around $3.4 billion (3.0 billion euros) after adjusting for the biotech firm's cash reserves.
SpringWorks Therapeutics specializes in developing targeted therapies for severe rare diseases and cancers, with its lead product, nirogacestat, positioned to treat desmoid tumors. The acquisition will give Merck access to a promising late-stage oncology asset and enhance its long-term growth prospects in the competitive cancer treatment market.
This move aligns with Merck's strategic focus on innovation and expanding its specialty medicine portfolio. The transaction is expected to strengthen its presence in the U.S. biotech sector and accelerate the development of novel oncology solutions for patients worldwide.
The acquisition is subject to customary closing conditions, including regulatory approvals, and is expected to finalize later this year.
